| 1 |
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer |
Limited Stage Small Cell Lung Cancer |
Combination Product: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy |
Shanghai Pulmonary Hospital, Shanghai, China|Jiangsu HengRui Medicine Co., Ltd. |
Phase 3 |
NCT05496166 |
2023-08-01 |
| 2 |
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above |
COVID-19 |
Biological: One dose group|Biological: Two doses group|Biological: Aged 18-59 years|Biological: Aged 60 years old and above |
Guangzhou Patronus Biotech Co., Ltd.|Yantai Patronus Biotech Co., Ltd. |
Phase 2 |
NCT05663086 |
2023-06-30 |
| 3 |
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer |
Advanced Colorectal Carcinoma |
Biological: OH2|Drug: Capecitabine|Drug: Bevacizumab |
Binhui Biopharmaceutical Co., Ltd. |
Phase 2 |
NCT05648006 |
2023-06-01 |
| 4 |
A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment |
Esophageal Squamous Cell Carcinoma |
Drug: Paclitaxel|Drug: Irinotecan|Biological: Pembrolizumab|Biological: MK-4830|Drug: Lenvatinib |
Merck Sharp & Dohme LLC |
Phase 1|Phase 2 |
NCT05319730 |
2023-05-05 |
| 5 |
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
Recurrent Glioblastoma |
Genetic: Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes. |
Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Tasly Pharmaceutical Group Co., Ltd |
Phase 1 |
NCT05577091 |
2023-05-01 |
| 6 |
A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants |
Healthy |
Drug: JNJ-77474462 |
Janssen Research & Development, LLC |
Phase 1 |
NCT05252520 |
2023-05-01 |
| 7 |
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer |
Advanced Biliary Tract Cancer |
Drug: IBI310|Drug: sintilimab |
Innovent Biologics (Suzhou) Co. Ltd. |
Phase 1|Phase 2 |
NCT05653180 |
2023-03-10 |
| 8 |
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong |
COVID-19 |
Biological: COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Biological: COVID-19 Vaccine (Vero Cell), Inactivated (High-dose) |
Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd |
Phase 2 |
NCT05254236 |
2023-03-10 |
| 9 |
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) |
Systemic Lupus Erythematosus |
Drug: Ianalumab|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05639114 |
2023-03-02 |
| 10 |
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration |
Neovascular Age-related Macular Degeneration |
Biological: ASKG712 |
AskGene Pharma, Inc.|Suzhou Aosaikang Biopharmaceutical Co., Ltd. |
Phase 1 |
NCT05456828 |
2023-02-20 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.